Kamada (NASDAQ:KMDA) Posts Quarterly Earnings Results

Kamada (NASDAQ:KMDA) released its quarterly earnings data on Monday. The biotechnology company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01), Zacks reports. Kamada had a net margin of 11.22% and a return on equity of 7.41%. Kamada updated its FY 2025 guidance to EPS.

Kamada Stock Performance

Shares of KMDA stock opened at $7.04 on Monday. The stock has a market capitalization of $405.07 million, a price-to-earnings ratio of 20.81, a PEG ratio of 0.70 and a beta of 0.81. The company’s 50-day simple moving average is $6.89 and its 200-day simple moving average is $7.08. Kamada has a one year low of $5.54 and a one year high of $9.15.

Institutional Investors Weigh In On Kamada

Several hedge funds have recently modified their holdings of KMDA. Jane Street Group LLC bought a new stake in Kamada during the first quarter worth approximately $582,000. Goldman Sachs Group Inc. acquired a new position in shares of Kamada during the 1st quarter worth about $497,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of Kamada in the 2nd quarter valued at about $472,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Kamada in the 1st quarter valued at approximately $206,000. Finally, Jump Financial LLC bought a new position in Kamada during the 2nd quarter worth approximately $219,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Kamada has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.